Cargando…

Sodium–Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions

Detalles Bibliográficos
Autores principales:	Misaghian-Xanthos, Negin, Shariff, Afreen I., Mekala, Kavya, Fearrington, Loretta R., Setji, Tracy L., Aloi, Joseph A., Buse, John B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2017
Materias:	e-Letters: Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439416/ https://www.ncbi.nlm.nih.gov/pubmed/28351898 http://dx.doi.org/10.2337/dc16-2591

Ejemplares similares

Periprocedural Euglycemic Diabetic Ketoacidosis Associated With Sodium–Glucose Cotransporter 2 Inhibitor Therapy During Colonoscopy
por: Meyer, Emily J., et al.
Publicado: (2020)

Cigarette Smoking as a Predictor of Sodium–Glucose Cotransporter 2 Inhibitor–Associated Genital Infections: A Retrospective Cohort Study
por: Scoccimarro, Daniele, et al.
Publicado: (2021)

Management of Diabetic Ketoacidosis in Severe Insulin Resistance
por: Robinson, Cemre, et al.
Publicado: (2016)

Fetal Outcomes After Diabetic Ketoacidosis During Pregnancy
por: Morrison, Fritha J.R., et al.
Publicado: (2017)

Diabetes Presentation in Infancy: High Risk of Diabetic Ketoacidosis
por: Letourneau, Lisa R., et al.
Publicado: (2017)

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
por: Peters, Anne L., et al.
Publicado: (2015)

Incidence and Clinical Features of Diabetic Ketoacidosis After Bariatric and Metabolic Surgery
por: Aminian, Ali, et al.
Publicado: (2016)

Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia
por: Gammons, D. Taylor, et al.
Publicado: (2018)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
por: Kelmenson, Daniel A., et al.
Publicado: (2017)

Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease
por: Bellanti, Francesco, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors and Euglycemic Diabetic Ketoacidosis: Metabolic Acidosis With a Twist
por: Jaberi, Aala, et al.
Publicado: (2016)

Sodium-glucose Cotransporter-2 Inhibitors and Euglycaemic Diabetic Ketoacidosis in the Perioperative Period: Case Report
por: Jhaveri, Urmita, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibitor-Related Diabetic Ketoacidosis: Accuracy Verification of Operational Definition
por: Kang, Dong Yoon, et al.
Publicado: (2022)

Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2020)

Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System
por: Wang, Tiansheng, et al.
Publicado: (2019)

Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes
por: Zaccardi, Francesco, et al.
Publicado: (2021)

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes
por: Bjornstad, Petter, et al.
Publicado: (2018)

Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting
por: Wang, Tiansheng, et al.
Publicado: (2019)

Metabolic ketoacidosis with normal blood glucose: A rare complication of sodium–glucose cotransporter 2 inhibitors
por: Ullah, Saad, et al.
Publicado: (2016)

Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes
por: Stinkens, Kirsten, et al.
Publicado: (2016)

A Review of the Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis
por: Zurek, Ashley M., et al.
Publicado: (2017)

Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases
por: Stamatiades, G. A., et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports
por: Seki, Hiroyuki, et al.
Publicado: (2023)

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
por: Danne, Thomas, et al.
Publicado: (2019)

Hypertriglyceridemia-Induced Acute Pancreatitis, Euglycemic Diabetic Ketoacidosis and COVID-19 Infection in a Patient With Type 2 Diabetes Taking a Sodium-Glucose Cotransporter 2 Inhibitor
por: Acevedo-Mendez, Bernardo A, et al.
Publicado: (2021)

Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
por: Crowley, Matthew J., et al.
Publicado: (2020)

Euglycemic Diabetic Ketoacidosis Due to Sodium–Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy
por: Pace, Devon J., et al.
Publicado: (2018)

SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor
por: Attia, Jonven, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis Followed by Excessively Low Carbohydrate Diet
por: Tsutsui, Erika, et al.
Publicado: (2021)

Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction
por: Cavka, Luka, et al.
Publicado: (2021)

Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis
por: Stougaard, Elisabeth B, et al.
Publicado: (2022)

Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports
por: Juneja, Deven, et al.
Publicado: (2023)

Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet
por: Hayami, Tomohide, et al.
Publicado: (2015)

Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature
por: Diaz-Ramos, Alexis, et al.
Publicado: (2019)

Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers
por: Somagutta, Manoj R, et al.
Publicado: (2021)

Multicentre prospective observational study of sodium-glucose cotransporter-2 inhibitor-associated postoperative ketoacidosis: the SAPKA study protocol
por: Seki, Hiroyuki, et al.
Publicado: (2021)

Sodium–glucose cotransporter‐2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature
por: Bitar, Zouheir Ibrahim, et al.
Publicado: (2022)

“The Bitter Truth of Sugar”—Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series
por: Shah, Mehul, et al.
Publicado: (2022)

Euglycemic diabetic ketoacidosis induced by sodium-glucose cotransporter 2 inhibitor in the setting of prolonged fasting: a case report
por: Alkatheeri, Abrar, et al.
Publicado: (2022)

SAT110 Euglycemic Diabetes Ketoacidosis Associated With Sodium-glucose Cotransporter Inhibitors: A Case Series To Raise Awareness
por: Katwal, Dilasha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f67sc3bsr39n40on9a3ir7relp